XL388 100mg 100mg | Purity Not Available
Adooq Bioscience
XL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).
More Information Supplier PageXL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).
More Information Supplier PageXL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).
More Information Supplier PageXL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity.
More Information Supplier PageAZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity.
More Information Supplier PageAZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity.
More Information Supplier PageMifamurtide is a liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities
More Information Supplier PageRuboxistaurin (LY333531) is a potent, selective inhibitor of Protein Kinase C isozymes, PKC ?? I(IC50=4.7 nM) and PKC ?? II (IC50=5.9 nM).
More Information Supplier PageRuboxistaurin (LY333531) is a potent, selective inhibitor of Protein Kinase C isozymes, PKC ?? I(IC50=4.7 nM) and PKC ?? II (IC50=5.9 nM).
More Information Supplier PageRuboxistaurin (LY333531) is a potent, selective inhibitor of Protein Kinase C isozymes, PKC ?? I(IC50=4.7 nM) and PKC ?? II (IC50=5.9 nM).
More Information Supplier PageRuboxistaurin (LY333531) is a potent, selective inhibitor of Protein Kinase C isozymes, PKC ?? I(IC50=4.7 nM) and PKC ?? II (IC50=5.9 nM).
More Information Supplier Page